Quotes 5-day view Delayed Nasdaq
01/23/2023
01/24/2023
01/25/2023
01/26/2023
01/27/2023
Date
3.5(c)
3.62(c)
3.55(c)
3.81(c)
3.7(c)
Last
581 672
682 260
581 605
542 616
529 552
Volume
+2.64%
+3.43%
-1.93%
+7.32%
-2.89%
Change
Estimated financial data (e) (USD)
Sales 2022
268 M
-
-
Net income 2022
-39,2 M
-
-
Net Debt 2022
-
-
-
P/E ratio 2022
-11,1x
Yield 2022
-
Sales 2023
304 M
-
-
Net income 2023
-21,0 M
-
-
Net Debt 2023
-
-
-
P/E ratio 2023
-20,2x
Yield 2023
-
Capitalization
420 M
420 M
-
Capi. / Sales 2022
1,57x
Capi. / Sales 2023
1,38x
Nbr of Employees
811
Free-Float
95,9%
MiMedx Group, Inc. is a transformational placental biologics company, developing and distributing placental tissue allografts for multiple sectors of healthcare. The Company is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company’s primary platform technologies include EPIFIX, AMNIOFIX, EPICORD, and AMNIOCORD....
Ratings of MiMedx Group, Inc.
All news about MIMEDX GROUP, INC.
01/09 MiMedx Reiterates Q4, 2022 Sales Outlook; Shares Rise MT
01/09 Mimedx Group, Inc. : Results of Operations and Financial Condition, Regulation FD Disclosu.. AQ
01/09 MIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on E.. AQ
01/09 MiMedx Group, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022 CI
01/05 MIMEDX Announces Commercial Launch Of EPIFIX In Japan With Exclusive Distribution Agree.. AQ
01/04 MiMedx Signs Distribution Deal with Gunze Medical to Sell EPIFIX in Japan MT
01/04 MiMedx Sings Distribution Deal with Gunze Medical to Sell EPIFIX in Japan MT
01/04 MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agre.. AQ
01/04 Mimedx Announces Commercial Launch of Epifix® in Japan with Exclusive Distribution Agre.. CI
01/03 Mimedx Group, Inc. : Change in Directors or Principal Officers, Financial Statements and E.. AQ
01/03 MiMedx Group Names Ricci Whitlow COO MT
01/03 MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer AQ
01/03 MiMedx Group, Inc. Appoints Ricci S. Whitlow as Chief Operating Officer CI
2022 Mimedx Group, Inc. : Change in Directors or Principal Officers (form 8-K) AQ
2022 MiMedx Group, Inc. Announces the Resignation of Rohit Kashyap as President, Wound Care .. CI
News in other languages on MIMEDX GROUP, INC.
Analyst Recommendations on MIMEDX GROUP, INC.
ETFs positioned on MIMEDX GROUP, INC. ETFs and Trackers with Trackinsight
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends MIMEDX GROUP, INC.
Short Term Mid-Term Long Term Trends Bullish Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3,70 $
Average target price
10,25 $
Spread / Average Target
177%
Please enable JavaScript in your browser's settings to use dynamic charts.